ArticleTranslational vision science & technology2025
Systematic Druggable-Proteome-Wide Mendelian Randomization Identifies Potential Therapeutic Targets for Allergic Conjunctivitis.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Allergic conjunctivitis (AC) is a prevalent ocular inflammatory condition. In this study, we aimed to identify novel therapeutic targets for AC by integrating druggable proteomic analyses. Methods: We sourced druggable protein abundance data from quantitative trait loci studies, including the deCODE Genetics Consortium (discovery) and UK Biobank Pharma Proteomics Project (replication). Genetic associations with AC were obtained from the FinnGen Project. We applied summary data-based Mendelian randomization (MR) and colocalization techniques to identify and prioritize potential therapeutic targets. Additionally, we conducted phenome-wide MR analysis to evaluate potential co-therapeutic benefits and adverse effects of identified candidate targets and performed protein-protein interaction analysis for functional validation. Results: Overall, 106 druggable proteins were significantly associated with AC. After false discovery rate (FDR) correction and eliminating associations potentially attributed to pleiotropy, CD36 and HSPA1B were identified as tier 1 and IL6R as tier 2 therapeutic targets. Genetically predicted higher levels of CD36 (odds ratio [OR], 0.78; 95% confidence interval [CI], 0.7-0.88, PFDR = 0.003) and HSPA1B (OR, 0.33; 95% CI, 0.22-0.52; PFDR < 0.001) were associated with a reduced risk of AC. Higher levels of IL6R (OR, 1.05; 95% CI, 1.03-1.07; PFDR < 0.001) were linked to an increased risk of AC. Colocalization was confirmed for CD36 (posterior probability H4 [PPH4] = 0.974) and HSPA1B (PPH4 = 0.974). In the phenome-wide MR analysis, targeting CD36 in patients with AC indicated no significant side effects after FDR correction. Conclusions: We identified three potential therapeutic targets, with CD36 being the most promising. Translational Relevance: These findings enhance our understanding of AC pathophysiology, driving the development of innovative treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.